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Background: MyD88 is an adaptor protein for TLR-4 signaling known to mediate paclitaxel resistance in epithelial
ovarian carcinoma (EOC). This study examined the clinical significance of MyD88 expression in EOC.
Methods: MyD88 and TLR-4 expression were examined by immunocytochemistry in 109 specimens of ovarian
tissues, comprising EOC (N = 83), borderline tumors (N = 9), benign cysts (N = 9) and normal ovarian tissue (N = 8),
and clinical data collected by a retrospective chart review. The correlations between MyD88 expression and
clinicopathological factors and outcomes were analyzed.
Results: TLR-4 expression was detected frequently in all the ovarian tissues. Distinct MyD88 expression was showed in
EOC (64 of 83, 77.1 %), in borderline tumors (5 of 9, 55.6 %) and in benign cysts (3 of 9, 33.3 %), and normal ovarian
tissue showed no MyD88 expression. Positive MyD88 expression significantly correlated with shorter disease-free and
overall survival for EOC (P< 0.0001 and P= 0.0031), and high MyD88 expression was significantly correlated with tumor
metastasis (P = 0.0012) for EOC. Univariate and multivariate analyses revealed that MyD88 expression was an
independent prognostic factor for disease-free survival and overall survival for EOC.
Conclusion: Our data indicate that MyD88 expression is a significantly poor prognostic factor for EOC. A better
understanding of the role of MyD88 expression in disease progression and outcome may be helpful for development
of novel chemotherapies for patients with EOC.
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Epithelial ovarian cancer (EOC) is one of the most lethal
malignant tumors in women, and the first leading cause
of death from gynaecological cancers [1,2]. Some 85 % to
90 % of ovarian cancers are epithelial, and more than
two thirds are diagnosed at an advanced stage. Cytore-
ductive surgery followed by paclitaxel/platinum-based
combination chemotherapy is still current management
strategies for EOC [3]. Although many tumors initially
respond to chemotherapy, patients with metastatic and/
or relapsed disease continue to have extremely poor sur-
vival outcomes [4,5].* Correspondence: zhanggn@hotmail.com
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reproduction in any medium, provided the orThe innate immune system recognizes the presence of
bacterial pathogens through the expression of a family
known as Toll-like receptors (TLRs) [6].TLRs recognize mi-
crobial-associated or host-associated pathogen-associated
molecular patterns (PAMP), which leads to the production
of proinflammatory cytokines [7,8]. Chronic infection and
inflammation are considered to be some of the most im-
portant epigenetic and environmental factors contributing
to tumorigenesis and tumor progession [9]. Myeloid differ-
entiation protein 88 (MyD88), a TLRs signaling adaptor
protein, is an essential downstream component of the TLRs
signalling cascade, and recent studies point to a critical role
for MyD88 in the protumorigenic inflammatory response
[10,11]. It has demonstrated that MyD88 is a novel, cell-au-
tonomous role in RAS signalling, cell-cycle control and cell
transformation through its interaction with activated Erk
[12].
Recent evidence has identified the contribution of
TLR-4MyD88 signaling pathway to epithelial ovarian car-
cinogenesis, development and a poor response to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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paclitaxel [13], EOC cells that express MyD88 constitu-
tively secrete pro-inflammatory cytokines, including
interleukin (IL)-6, IL-8, vascular endothelial growth fac-
tor (VEGF) and monocyte chemotactic protein (MCP),
which mediates tumor progression, invasion, metastasis
and paclitaxel chemoresponse [14-17]. However, little is
known about the clinicopathological factors and prog-
nostic significance of MyD88 expression in EOC. Investi-
gation of MyD88 status is needed to differenciate those
patients with EOC. By detecting levels of MyD88 expres-
sion, it might be possible to identify those patients with
EOC most likely to benefit from adjuvant chemotherapy
and target treatment accordingly. Therefore, a better
understanding of MyD88 as a potential marker is needed
to further optimize treatment strategies, to develop new
chemotherapeutic agents and to evaluate prognostic sig-
nificance of EOC.
The objective of this study was to investigate the prog-
nostic significance of immunohistochemical detection of
MyD88 expression and its association with clinicopatho-
logical factors in patients with EOC.Methods
Tumer cell lines
Human EOC cell lines SKOV-3 and A2780 were pur-
chased from the Committee on Type Culture Collection
of Chinese Academy of Sciences (CTCCCAS,Shanghai,
China). Cell lines were maintained in culture in 75 cm
flasks with RPMI 1640 medium (GIBCO, Invitrogen),
supplemented with 2 mmol/L L-glutamine, 10 % heat-
inactivated fetal calf serum (FCS), 100 U/ml penicillin
and 40U/ml Gentamicin, in a humidified atmosphere of
5 % CO2 and 95 % air. Subconfluent cells (80 %) were
passaged with a solution containing 0.25 % trypsin and
0.5 mmol/L EDTA.Patients and human tissues
A total of 109 patients who underwent surgery from
1999 to 2009 at the Sichuan Cancer Hospital were inves-
tigated in this study. Information on patient demograph-
ics (age) and tumor features (pathology, histological
grade, FIGO stage, lymph node metastasis, malignant
cells in ascites, liver or lung metastasis, and residual
tumor) was obtained from clinical and pathological
records (Table 1). Disease stages were classified accord-
ing to the criteria proposed by the FIGO (International
Federation of Gynecology and Obstetrics). Tissue collec-
tion was done before chemotherapy. All patients
received six to eight cycles of paclitaxel/carboplatin (TP)
regimen after surgery. Exclusion criteria were cancers
associated with sex cord-stromal tumors, germ cell
tumor, or secondary tumors. All patients, enrolled in thisstudy, had signed informed consent, approved by our In-
ternal Ethical Committee.
For the immunohistochemical study, formalin-fixed,
paraffin-embedded tissue samples from normal ovarian
tissue (n = 8) obtained by oophorectomy, as well as be-
nign cysts (n = 9), borderline tumors (n = 9), and EOC
(n= 83), were used.
SDS-PAGE and Western blots
SKOV-3 and A2780 cells were lysed in RIPA buffer [1 %
Triton X-100, 150 mmol/L NaCl, 1 mmol/L EGTA,
50 mmol/L Tris–HCl, 0.1 % sodium dodecyl sulfate (SDS),
1 % sodium desoxycholate and phenylmethylsuphonyl
fluoride (PMSF)] and disrupted by sonication on ice. Cell
lysates were centrifuged at 12 000 rpm for 20 min at 4°C,
the supernatant was used for TLR4 and MyD88 protein
determination by western blots. Twenty μg of total protein
from each cell lysate ( Bradford assay ) were separated on
a 8 % ( for TLR4) and 12 % ( for MyD88) polyacrylamide/
SDS gel. After protein transfer (BIO-RAD Trans-BlotW SD
for 30 min) to a polyvinylidene difluoride membrane
(BIO-RAD Sequi-BlotTM PVDF membrane, US), the
membranes were incubated in blocking buffer for 1 hour
and then incubated with rabbit anti-human TLR4 and
MyD88 Abs (dilution 1:1000; Epitomics and Abcam, US)
overnight at 4°C. After washing, the membranes were
incubated with a horseradish peroxidase-labeled goat anti-
rabbit IgG (1:10 000 dilution; SANTA, US) for 1 hour at
room temperature. For protein detection, membranes were
incubated with ECL-substrate for 5 min (CoWin Biotech,
Beijing, China). The band intensities were digitalized
and quantified using the ChemiDoc XRS + software
(Bio-Rad, US).
Immunohistochemistry for TLR4 and MyD88
SKOV-3 and A2780 cells were grown on covered glass
slides in culture medium for 48 hours. Cells were fixed with
methyl alcohol and acetone (1:1) for 10 min at −20°C; Paraf-
fin section of tumor tissues (4-μm) were deparaffinized in
xylene and rehydrated in a series of ethanols, and antigen
retrieval was performed using an autoclave oven technique.
The slides were then placed in a staining dish with 0.3 per-
cent H2O2 to quench for endogenous peroxidase activity
for 30 min and washed with PBS three times. The area
around the tissue sections or cell slides was scored with a
Pap pen to limit the amount of antibodies and reagents
used. All steps occurred at room temperature with the
slides placed in a moisture chamber to keep the tissue or
cell from drying out during the procedure. To block for
non-specific background, 100–200 μl of 5 % BSA made in
PBS were added to the circumscribed areas and incubated
for 20 min in the moisture chamber. Next, the primary anti-
body (4 – 5 μg/ml) was incubated overnight at 4°C with the
primary antibody (4 – 5 μg/ml) followed by washing with
Table 1 Clinicopathological features according to TLR4 and MyD88 expression
TLR4 MyD88 MyD88+
High Low Positive Negative High Low
Clinicopathological factors (n = 67 ) (n = 16 ) P-value (n = 64 ) (n = 19 ) P-value (n = 28 ) (n = 36 ) P-value
Age(years)
≥55 32 11 0.1311 29 14 0.0268 11 18 0.2743
<55 35 5 35 5 17 18
Pathology
Serous 50 12 0.6249 46 15 0.3850 21 25 0.4190
Other 17 4 18 4 7 11
Histological grade
Well /Moderate 23 6 0.5135 25 4 0.1192 15 10 0.0328
Poor/ Clear cell 44 10 39 15 13 26
FIGO Stage
I, II 11 1 0.2742 9 3 0.5528 5 4 0.3393
III, IV 56 15 55 16 23 32
Malignant cells in ascites
Yes 34 4 0.0555 32 6 0.1240 12 20 0.2250
No 33 12 32 13 16 16
Lymph node metastasis
Yes 20 2 0.1345 20 2 0.0610 15 5 0.0008
No 47 14 44 17 13 31
Liver or lung metastasis
Yes 25 4 0.2666 27 2 0.0087 16 11 0.0298
No 42 12 37 17 12 25
Residual tumor
>1 32 6 0.3244 32 6 0.1240 14 18 0.5993
<1 35 10 32 13 14 18
Abbreviations: TLR4 = Toll-like receptor 4; MyD88=myeloid differentiation factor 88. Bold values indicate P< 0.05.
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nylated anti-rabbit IgG (5 μg/ml) and horseradish peroxid-
ase streptavidin (4 μg/ml) for 50 min at 37°C. The color was
developed with DAB (2.5 mg 3, 3’-diaminobenzidine in
5 ml 0.1 mol/L Tris). Twenty five μl of 0.03 percent H2O2
were added to the chromogen just before use. The slides
were washed with double distilled water and counterstained
lightly with hematoxylin and mounted in glycerol jelly.
Human SKOV-3 cell line was used as a positive control for
TLR4 and MyD88 immunoreactivity. PBS without the pri-
mary antibody served as negative control.Evaluation of immunohistochemical findings
Each slide was evaluated independently by two pathologists
who were blinded to clinical and outcome data. As most
samples stained for TLR4 and MyD88 showed similar color
intensity, from moderate to strong, no evaluation of color
intensity was performed in this study. Any intensity of
membrane and/or cytoplasmic staining was considered torepresent a positive stain for TLR4 and MyD88. Several
high-power fields (×400) selected from different staining
density regions including high, moderate, low, and negative
staining areas were captured using a digital camera (Olym-
pus IX71 Inverted Fluorescence Microscope and AnalySIS
image capture software). Photographs were printed on plain
paper and a grid was drawn over them. We counted a mean
of 2 000 tumor cells per tumor (range, 1 500 – 2 500), and
results were expressed as the percentage of tumor cells with
a positive stain. Thereafter, the percentage of TLR4- or
MyD88-positive tumor cells was scored on a scale of 0 – 4
(0: no staining; 1+: ≤10 %; 2+: 11-30 %; 3+: 31-50 %; 4+:
>50 %). Furthermore, the expression levels of TLR4 and
MyD88 were divided into the follow two groups according
to score: low (1+, 2+) and high (3+, 4+).Statistical analysis
Analysis was performed using SPSS 17.0 software. The
Pearson χ2 exact test or Fisher’s exact test was used to
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outcomes were DFS and OS measured from the day of
surgery. DFS was defined as the interval between the day
that surgery was performed and the day that recurrence
was first detected. If recurrence was not diagnosed, the
date of death or of last follow-up was used. OS was
defined as the interval between the dates of surgery and
death. The follow-up period after the initial operation for
the primary lesion was 5 years for DFS and OS. Both
DFS and OS were estimated by Kaplan-Meier curves,
and the curves were compared using the log-rank test.
Time to relapse and to death was analyzed using the Cox
proportional hazards model for univariate and multivari-
ate analyses. In addition, the hazard ratios (HRs) between
prognostic groups and their 95 % confidence intervals
were computed. Probability values (P)< 0.05 were con-
sidered to be statistically significant.
Results
Expression of TLR4 and MyD88 in ovarian cancer cell lines
and tissues
The TLR4 and MyD88 expression were evaluated in human
EOC cell lines and tumor sections. Positive immunoreactiv-
ity for TLR4 was observed in SKOV-3 and A2780 and posi-
tive immunoreactivity for MyD88 only in SKOV-3 byFigure 1 A. TLR4 and MyD88 expression in EOC cell lines. Immunostain
for MyD88 protein in SKOV-3 (b) and A2780 (e) (×400). Negative stainging for
SKOV-3 and A2780 cell lines by using Western blot assays. C. The expression r
The positive rates of MyD88 in normal ovarian tissue, benign cysts, borderline
expression of TLR4 was correlated with high expression of MyD88 in EOC. EOC
of MyD88 expression than did EOC with a low expression of TLR4 (N= 16) (P=
significantly high levels of TLR4 expression than did EOC with a low expressiostaining of cell crawled-slides (Figure 1A) and by western
blotting (Figure 1B). No staining was observed when PBS
was used as a negative control. The SKOV-3 cell line was
obtained from the ascites of a patient with advanced, meta-
static EOC. SKOV-3 is resistant to most cytotoxic drugs
[18]. In contrast, the A2780 cell line was derived from a pri-
mary untreated and paclitaxel-sensitive cancer [19].
Immunolocalization of TLR4 protein was observed in
the membrane and cytoplasm. In general, TLR4 was
found to be expressed in normal ovarian epithelium
(Figure 2a, b), benign cysts (Figure 2e, f ), borderline
tumors (Figure 2m, n) and malignant tumors (Figure 2i,
j). However, the intensity of staining for TLR4 in malig-
nant tumors was considerably greater than that in nor-
mal tissues or benign tumors. Normal ovarian
epithelium did not express TLR4 signaling adapter pro-
tein, MyD88 (Figure 2c, d). MyD88 expression was
observed in benign cysts, but greatest in borderline and
malignant tumours (Figure 1C). In EOC, a total of 64 of
83 (77.11 %) cancers showed MyD88 expression, but a
variably strong or weak signal (4+: 9, 3+: 19, 2+: 18, 1+:
18, 0: 19) (Figure 2o, p).
In the co-expression analysis, MyD88 expression levels
were higher in TLR4 high-expression EOC than in TLR4
low-expression EOC (P=0.0045, Figure 1D-a). Similarly,ing for TLR4 protein in SKOV-3 (a) and A2780 (d) (×400). Immunostaining
TLR4 and MyD88 using PBS (c, f). B. Expression of TLR4 and MyD88 in
ates of MyD88 were gradually increased with the progress ovarian lesions.
tumors and EOC were 0, 33.3 %, 55.6 % and 77.1 %. D. (a) High
with a high expression of TLR4 (N= 67) showed significantly high levels
0.0045). (b) EOC with a high expression of MyD88 (N=28) showed
n of MyD88 (N=55) (P= 0.0117).
Figure 2 Expression of TLR4 and MyD88 in normal ovarian tissue, benign cysts, borderline tumors and EOC. Detection of TLR4 and
MyD88 immunoreactivity in normal ovarian tissue (a-d), benign cysts (e-h), borderline tumors (i-l), and EOC (m-p). Original magnification, (a, c, e, g,
i, k, m, o) × 200; (b, d, f, h, j, l, n, p) × 400. Normal ovarian tissue showed no or weak immunoreactions for TLR4 (a, b). Strong immunostaining of
TLR4, which was localized in the membrane or cytoplasm, was observed in the benign cysts (e, f), borderline tumors (i, j) and EOC (m, n). In
contrast to the situation in the normal ovarian tissue (c, d), benign cysts (g, h), borderline tumors (k, l), strong immunostaining of MyD88, which
was localized in the cytoplasm, was vserved in EOC (o, p).
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with high MyD88 expression (P= 0.0117, Figure 1D-b). Fi-
nally, the correlation between the expression of TLR4 and
MyD88 in EOC was confirmed using Pearson’s correlation
coefficient analysis (r = 0.28, P= 0.0093) and Spearman’s
correlation coefficient analysis (P= 0.0093). In addition, 40(48 %) cancers showed a high-level combined expression
of TLR4/MyD88 (6+: 17, 7+: 15, 8+: 8).
Clinicopathological significance of TLR4 and MyD88
The co-distribution of EOC with a differentiated TLR4/
MyD88 expression in relation to cancer and patient
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expression of MyD88 was significantly associated with
histological grade (P = 0.0113), lymph node metastasis
(P = 0.0001) and liver or lung metastasis (P = 0.0029).
Furthermore, expression of MyD88 was significantly
associated with age (P = 0.0268).Clinicopathological parameters and patient survival in
EOC
At the 5-years follow-up, 49 patients had recurrence
(DFS rate: 59.0 %), and 35 patients had died (OS rate:
42.2 %). In univariate analysis, FIGO stage (DFS,
P = 0.0137; OS, P = 0.0368), malignant cells in ascites
(DFS, P = 0.0242; OS, P = 0.1913), lymph node metastasis
(DFS, P = 0.0001; OS, P = 0.0076), liver or lung metastasis
(DFS, P< 0.0001; OS, P = 0.0003) and residual tumor
(DFS, P = 0.0164; OS, P = 0.0950) were important factors
associated with DFS and OS. Patient age, pathology and
histological grade were not related to DFS or OS
(Table 3A). Multivariate analysis was performed to iden-
tify independent prognostic factors. Models that include
all histopathological variables and tumor markers found
to have significant prognostic value in univariate analysis
are shown. FIGO stage was significantly associated with
DFS (P = 0.0446) and OS (P = 0.0468), and the presence
of liver or lung metastasis was significantly associated
with DFS (P = 0.0380) and OS (P = 0.0237) (Table 3B).TLR4 and MyD88 expression and patient survival in EOC
We assessed the influence of expression of TLR4 and
MyD88 in EOC on patient survival. Patients with a high
TLR4 expression had a worse DFS and OS than did those
with a low TLR4 expression (median DFS: 20.73 vs.Table 2 Clinicopathological features according to differentiat
Negative Low Nega
Clinicopathological factors (n = 19 ) (n = 36 ) P-value (n = 1
Age(years)
≥55 14 18 0.0787 14
<55 5 18 5
Histological grade
Well /Moderate 4 10 0.4202 4
Poor/ Clear cell 15 26 15
Lymph node metastasis
Yes 2 5 0.5412 2
No 17 31 17
Liver or lung metastasis
Yes 2 11 0.0888 2
No 17 25 17
Abbreviations: MyD88=myeloid differentiation factor 88. Bold values indicate P< 029.73 months; median OS: 31.77 vs. 66.30). However, a
high expression of TLR4 did not significantly influence
DFS (log-rank P=0.1657; Figure 3a) and OS (log-rank
P=0.2685; Figure 3b). Expression of MyD88 was signifi-
cantly related to poor DFS (log-rank P= 0.0014, Figure 3c)
and OS (log-rank P= 0.0185, Figure 3d). In addition,
patients whose tumors expressed low-MyD88 had a statis-
tically significant improved DFS and OS compared with
patients whose tumors expressed high-MyD88 (median
DFS: 12.02 vs 20.73 months, P = 0.0459; median OS: 22.87
vs. 36.47 months, P = 0.0395, respectively, Figure 3e, f).
In univariate analysis, high expression of TLR4 was not
significantly related to DFS and OS (Table 3A). Expres-
sion of MyD88 was significantly related to poor DFS
(HR: 0.10; 95 % CI: 0.02 – 0.41; P = 0.0014) and signifi-
cantly influenced OS (HR: 0.09; 95 % CI: 0.01 – 0.67;
P = 0.0185). In multivariate analysis, expression of
MyD88 was significantly associated with poor DFS
(adjusted HR: 0.11; 95 % CI: 0.23 – 0.47; P = 0.0027) and
OS (adjusted HR: 0.12; 95 % CI: 0.02 – 0.89; P = 0.0382)
(Table 3B).Discussion
It was recently reported that TLR4/MyD88 signalling
drives tumour growth in EOC with MyD88 positive ex-
pression. It has been known that TLR4/MyD88 signalling
in tumour cells itself has important roles as oncogenic
factors [20]. Silencing TLR4/MyD88 signalling in tumour
cells results in reduced tumour formation, and the inhib-
ition of tumour-cell apoptosis by MyD88-dependent
TLR4 signalling was observed in EOC [19,21]. Recent
reports revealed that TLR4/MyD88 signalling drives
tumour growth and chemoresistance to paclitaxel ined MyD88 expression
tive High Negative + low High
9 ) (n = 28 ) P-value (n = 55 ) (n = 28 ) P-value
11 0.0208 32 11 0.0811
17 23 17
15 0.0256 14 15 0.0113
13 41 13
15 0.0026 7 15 0.0001
13 48 13
16 0.0012 13 16 0.0029
12 42 12
.05.
Table 3 Clinicopathological features, tumor markers, and patient survival (univariate analysis)
Variable 5-Year DFS HR
(95 % CI)
P-value 5-Year OS HR
(95 % CI)
P-value
A. univariate analysis
Age (≥55 years vs <55 years) 0.77(0.43-1.36) 0.3659 0.76(0.38-1.51) 0.4313
Pathology (serous vs other) 0.51(0.24-1.09) 0.0833 0.69(0.29-1.67) 0.4100
Histological grade (poor vs well/moderate) 0.61(0.34-1.07) 0.0859 0.73(0.37-1.43) 0.3587
FIGO stage (III/IV vs I/II) 5.95(1.44-24.55) 0.0137 8.41(1.14-62.03) 0.0368
Malignant cells in ascites (yes vs no) 1.96(1.09-3.51) 0.0242 1.59(0.79-3.20) 0.1913
Lymph node metastasis (yes vs no) 3.29(1.99-6.03) 0.0001 2.55(1.28-5.07) 0.0076
Liver or lung metastasis (yes vs no) 4.28(2.35-7.80) <0.001 3.62(1.81-7.25) 0.0003
Residual tumor (>1 vs <1) 2.04(1.14-3.66) 0.0164 1.81(0.90-3.63) 0.0950
TLR4 (high vs low) 1.78(0.79-4.02) 0.1657 1.68(0.67-4.19) 0.2685
MyD88 (positive vs negative) 0.10(0.02-0.41) 0.0014 0.09(0.01-0.67) 0.0185
B. multivariate analysis
FIGO stage (III/IV vs I/II) 4.57(1.04-20.17) 0.0446 7.89(1.03-58.90) 0.0468
Malignant cells in ascites (yes vs no) 1.38(0.73-2.60) 0.3255 —— ——
Lymph node metastasis (yes vs no) 1.25(0.62-2.52) 0.5315 0.94(0.43-2.05) 0.8713
Liver or lung metastasis (yes vs no) 2.21(1.05-4.69) 0.0380 2.47(1.13-5.41) 0.0237
Residual tumor (>1 vs <1) 1.04(0.54-1.99) 0.9082 —— ——
MyD88 (high vs low) 0.11(0.23-0.47) 0.0027 0.12(0.02-0.89) 0.0382
Abbreviations: DFS = disease-free survival; HR = hazard ratio; CI = confidence interval; OS = overall survival; FIGO= International Federation of Gynecology and
Obstetrics; TLR4 = Toll-like receptor 4; MyD88 =myeloid differentiation factor 88. Bold values indicate P< 0.05.
Zhu et al. Journal of Translational Medicine 2012, 10:77 Page 7 of 10
http://www.translational-medicine.com/content/10/1/77EOC. In addition, MyD88 has been shown to be pivotal
for the resistance to paclitaxel and the promotion of
tumour progression in patients with EOC [20,22]. TLR4/
MyD88 signalling have been shown to be associated with
local chronic inflammation [22,23]. Activation of TLR4/
MyD88 signalling seems to promote the development of
EOC by mechanisms including enhanced expression of
proinflammatory cytokines. In this study, we observed
that TLR4 expression is ubiquitous in all detected ovar-
ian tissues, and that MyD88 was overexpressed in EOCs
compared with borderline tumors and benign cysts, but
not expressed in normal ovarian tissues. A subgroup of
EOC cells differentially expressing MyD88 has demon-
strated enhanced cytokine/chemokine production and
cellular proliferation upon activation of TLR4 [14-17].
The molecular pathway that links inflammation to the
acquisition of metastatic capacity during tumour pro-
gression has been investigated [24]. Recent reports sug-
gest that MyD88 expression of EOC cells may be
associated with the invasion and metastasis of tumor by
acquisition of epithelial mesenchymal transition(EMT)
phenotype. Our study showed that MyD88 overexpres-
sion was frequently detected in EOCs with lymph node
metastasis and liver or lung metastasis. Our findings
suggest that MyD88 overexpression promotes EOC pro-
gression by contributing to metastasis. MyD88 positive
EOC cells have a functioning TLR4/MyD88 pathwayand are possibly indicative of an ovarian cancer stem cell
that is highly resistant to pro-apoptotic signalling [25].
Recent reports have identified CD44 as a potential marker
for the identification of cancer stem cells in ovarian cancer,
and confirmed the functionality of the TLR4-MyD88 path-
way in only the CD44+ cell population [25,26]. CD44+
EOC cells express TLR-4 and MyD88 and respond to
TLR-4 ligands by activating NF-κB, promoting a pro-in-
flammatory microenvironment, and proliferating with
chemotherapy,suggesting that the TLR-4/MyD88 pathway
may play a critical role in the process of repair/differenti-
ation triggered by the cancer stem cells. Furthermore,
ex vivo manipulation of ovarian CSC differentiation can
significantly decrease MyD88 expression [27].
Blocking TLR4/MyD88 signalling would provide a
survival benefit. However, the association between
TLR4/MyD88 signalling and cancer mortality has not
been well investigated in clinical samples. Our results
clearly demonstrated that overexpression of MyD88 was
an independent and significant prognostic factor for
DFS and OS. In addition, patients whose tumors
expressed MyD88 were younger compared with patients
whose did not express MyD88. Recent clinical studies
have indicated that low-grade serous EOC is relatively
chemoresistant in the primary, neoadjuvant and recur-
rent settings, which was in agreement with our finding
that high expression of MyD88 closely depended upon
Figure 3 Kaplan-Meier survival curves of DFS and OS in patients with EOC according to TLR4 and MyD88 expression. (A, B) High
expression of TLR4 was potentially associated with poor DFS and OS (P = 0.1076, P = 0.2158, respectively). (C, D) High expression of MyD88 was
significantly associated with poor DFS and OS (P = 0.0007, P = 0.0008, respectively). (E, F) High co-expression of TLR4 +MyD88 was significantly
associated with poor DFS and OS (P< 0.0001, P = 0.0057, respectively).
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MyD88 expression is independent of histologic grade
and associated with significantly shorter patient survival
[27]. These results suggest that MyD88 expression may
be more important than histologic subtype or grade in
epithelial ovarian cancers but remains to be
determined.MyD88 negative EOC cells lack this functioning pathway
that are more responsive to apoptosis and therefore less
biologically aggressive [29,30], When MyD88 negative
EOC cells are transfected with MyD88, making them posi-
tive cells, resistance to paclitaxel is induced. Previous stud-
ies reported that elevation of the downstream signals of
the TLR4/MyD88 pathway, such as IL-6 and NF-κB was
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MyD88 regulates the expression of IL-6, which shows its
important role in many aspects of tumour growth. NF-κB
is an end point of the TLR4/MyD88 signalling pathway.
Numerous lines of evidence that link NF-kB activation to
cancer development have been reported. Our previous
studies showed that an antagonizing TLR4 sesquiterpenoid
compound from Atractylodes macrocephala Koidz could
downregulate the expression and release of IL-6 induced
by paclitaxel or LPS in MyD88 positive SKOV-3 cells,
which are more resistant to paclitaxel than MyD88 nega-
tive A2780 cells. These findings suggested that the tumour
cell TLR4/MyD88 signalling pathway has a crucial role in
EOC patient prognosis and that blocking this pathway
could provide great benefits for patients with EOC. We
evaluated the correlation between MyD88 expression and
clinical outcome, and we have found that all patients who
had MyD88 positive tumors presented with poor DFS and
OS, while the patients with MyD88 negative tumors had
an excellent prognostic outcome. Our study profiled the
status of MyD88 in ovarian tumour samples, and showed
the clinicopathological significance of tumour cell self-
MyD88 expression in EOC.
Conclusions
In conclusion, MyD88 overexpression was associated with
carcinogenesis and tumor progression of EOC and with an
increased risk of metastasis and worse survival, and the
identification of MyD88 expression as determined by
immunohistochemistry is a useful prognostic factor in
EOC. However, Our clinical conclusions about MyD88 ex-
pression as a prognostic marker in EOC were based on
retrospective analyses and are needed to be independently
validated.
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